Article
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Journal of clinical pharmacology - 1 Sept 2008
Kwara Awewura, Lartey Margaret, Sagoe Kwamena W, Xexemeku Fafa, Kenu Ernest, Oliver-Commey Joseph, Boima Vincent, Sagoe Augustine, Boamah Isaac, Greenblatt David J, Court Michael H
Abstract excerpt
The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/d) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer. In the 26 patients studied, CYP2B6 c.516GG, GT, and TT genotype frequencies were 0.27, 0.50, and 0.23, respectively. Mean plasma efavirenz area under the curve was significantly higher in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.